The Phase 1b/2 open label study of CLD-101 will evaluate the safety and feasibility of administering multiple doses of CLD-101 in patients with newly diagnosed high-grade glioma. Eligible patients, ...
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of ...
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, ...
The Dr. Dennis Gross DRx SPectralite Facewear Pro LED Mask uses red and blue therapy to minimize acne and fine lines. I ...
You may have heard about ketamine in the news, but did you know that the right dose of this medicine can stimulate your brain ...
Vuja De Sciences, Inc. ("Vuja De"), a biotechnology company dedicated to improving cancer patient outcomes by developing innovative therapies that target the unique vulnerabilities of micrometastatic ...
Direct Oral Anticoagulants (DOACs) have significantly improved anticoagulation therapy – due to their ease of use, ...
The Dr. Dennis Gross DRx SPectralite Facewear Pro LED Mask uses red and blue therapy to minimize acne and fine lines. I ...
ATLANTA, GA, USA I5, 2024 I UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with ...
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria ...
He reiterated FPCCI's stance that the Federal Board of Revenue's (FBR) revised tax collection target of Rs12.91 trillion for the fiscal year 2024-25 is not only unrealistic but also regressive and ...
This increase in the success probability has also prompted an increase in his price target for the stock from $5 to $9. The Hold rating also takes into account upcoming data updates for Biomea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback